𝔖 Bobbio Scriptorium
✦   LIBER   ✦

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma

✍ Scribed by Elkins, K.; Zheng, B.; Go, M.; Slaga, D.; Du, C.; Scales, S. J.; Yu, S.-F.; McBride, J.; de Tute, R.; Rawstron, A.; Jack, A. S.; Ebens, A.; Polson, A. G.

Book ID
115513775
Publisher
American Association for Cancer Research
Year
2012
Tongue
English
Weight
867 KB
Volume
11
Category
Article
ISSN
1535-7163

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Antibody-Drug Conjugates and Immunotoxin
Antibody-Drug Conjugates and Immunotoxins || Antibody–Drug Conjugates for the Treatment of B-Cell Malignancies
✍ Phillips, Gail Lewis πŸ“‚ Article πŸ“… 2012 πŸ› Springer New York 🌐 English βš– 267 KB

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Monoclonal antibody drug conjugates in t
Monoclonal antibody drug conjugates in the treatment of cancer
✍ Pamela A Trail; Albert B Bianchi πŸ“‚ Article πŸ“… 1999 πŸ› Elsevier Science 🌐 English βš– 79 KB

Monoclonal antibodies directed to tumor-associated antigens have been chemically conjugated to drugs with different mechanisms of action and different levels of potency. Monoclonal-antibody-directed drug delivery has the potential to both improve efficacy and reduce systemic toxicity. Several immuno